Fidelis Capital Partners LLC Grows Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Fidelis Capital Partners LLC increased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 12.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,785 shares of the pharmaceutical company’s stock after purchasing an additional 199 shares during the quarter. Fidelis Capital Partners LLC’s holdings in Vertex Pharmaceuticals were worth $726,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Arlington Trust Co LLC raised its stake in Vertex Pharmaceuticals by 97.1% during the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 33 shares during the last quarter. Fortitude Family Office LLC purchased a new position in Vertex Pharmaceuticals during the fourth quarter valued at $30,000. Baystate Wealth Management LLC raised its stake in Vertex Pharmaceuticals by 49.0% during the fourth quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after buying an additional 25 shares during the last quarter. OFI Invest Asset Management purchased a new position in Vertex Pharmaceuticals during the third quarter valued at $25,000. Finally, Cornerstone Planning Group LLC purchased a new position in Vertex Pharmaceuticals during the second quarter valued at $33,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Amit Sachdev sold 3,222 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the sale, the executive vice president now owns 74,364 shares of the company’s stock, valued at approximately $31,250,727.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Vertex Pharmaceuticals news, EVP Amit Sachdev sold 3,222 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the sale, the executive vice president now owns 74,364 shares of the company’s stock, valued at approximately $31,250,727.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Kristen Ambrose sold 1,374 shares of the stock in a transaction on Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $577,409.76. Following the sale, the chief accounting officer now directly owns 9,676 shares in the company, valued at approximately $4,066,242.24. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,381 shares of company stock valued at $5,203,249. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Trading Up 0.5 %

NASDAQ:VRTX traded up $2.10 during midday trading on Friday, hitting $395.58. The stock had a trading volume of 237,185 shares, compared to its average volume of 1,231,383. Vertex Pharmaceuticals Incorporated has a one year low of $316.43 and a one year high of $448.40. The company has a market capitalization of $102.24 billion, a price-to-earnings ratio of 28.33, a PEG ratio of 1.85 and a beta of 0.35. The stock has a 50-day moving average of $414.17 and a 200 day moving average of $396.74. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.85 by $0.35. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. The company had revenue of $2.52 billion for the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter in the prior year, the firm earned $3.33 earnings per share. As a group, sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on VRTX. Evercore ISI upgraded Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 price target for the company in a research note on Thursday, April 11th. Maxim Group cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Robert W. Baird lowered Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 price objective for the company. in a report on Wednesday, January 31st. StockNews.com raised Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, April 12th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $500.00 price objective on shares of Vertex Pharmaceuticals in a report on Monday. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $429.45.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.